Tandem Diabetes Care Inc. (NASDAQ:TNDM) was down 1.2% during mid-day trading on Thursday . The stock traded as low as $6.33 and last traded at $6.45, with a volume of 179,015 shares traded. The stock had previously closed at $6.53.

Several equities research analysts recently issued reports on TNDM shares. Robert W. Baird restated a “buy” rating on shares of Tandem Diabetes Care in a research report on Monday, May 2nd. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a research report on Wednesday, May 4th. Sterne Agee CRT restated a “neutral” rating on shares of Tandem Diabetes Care in a research report on Monday, May 16th. Finally, Wedbush restated an “outperform” rating and set a $20.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $14.21.

The company’s market capitalization is $203.58 million. The firm’s 50 day moving average price is $7.21 and its 200 day moving average price is $7.98.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, July 28th. The medical device company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.05. During the same period last year, the company earned ($0.65) earnings per share. The company had revenue of $23 million for the quarter, compared to analyst estimates of $23.08 million. The business’s revenue for the quarter was up 46.5% compared to the same quarter last year. On average, equities analysts anticipate that Tandem Diabetes Care Inc. will post ($2.14) EPS for the current year.

In related news, EVP John F. Sheridan sold 15,000 shares of the business’s stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $6.52, for a total value of $97,800.00. Following the sale, the executive vice president now directly owns 22,763 shares in the company, valued at approximately $148,414.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.